Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study A total of 3.4% (41/1,206) of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback